SciELO - Scientific Electronic Library Online

vol.33 issue2Emotional dependence of students of medicineAcute myocardial infarction in a patient with low cardiovascular risk and elevated lipoprotein (a). Case report author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista Medica Herediana

Print version ISSN 1018-130XOn-line version ISSN 1729-214X


DIAZ, Carol  and  ZAPATA, Carlos. Profound molecular response with ponatinib in chronic phase of chronic myeloid leukemia with resistance to imatinib and dasatinib: Case report and review of the literature. Rev Med Hered [online]. 2022, vol.33, n.2, pp.133-138.  Epub July 06, 2022. ISSN 1018-130X.

We report the case of a woman who at the age of 54 years was diagnosed with chronic myeloid leukemia in chronic phase; she began treatment with a first-generation tyrosine kinase inhibitor, and evidenced failure due to the absence of a hematological and cytogenetic response. Despite changing treatment to a second-generation tyrosine kinase inhibitor (dasatinib), it was not possible to achieve optimal levels of response, documenting positivity for the T315I mutation in the ABL domain of the deregulated BCR/ABL tyrosine kinase, compared to ponatinib, the only drug that shows activity. After starting treatment with ponatinib, optimal levels of cytogenetic and molecular response were evidenced, as well as an adequate quality of life for the patient.

Keywords : BCR-ABL positive chronic myelogenous leukemia; Protein Tyrosine Kinases; Philadelphia Chromosome.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )